Demand drives interest in oncology drug makers

While venture capital funds chase a shrinking number of deals in China, the pharmaceutical sector remains a bright light.

Apollomics, a Sino-US oncology drug company, has raised $100 million in Series B funding from a group of Chinese investors.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media